ANOGENITAL CANCER--EPIDEMIOLOGY, BIOCHEMISTRY, AND IMMUNOLOGY

这是一项继续进行病例对照研究的建议， 人乳头瘤病毒（HPV）在肛门生殖器发育中的作用 癌的该研究将主要在以下三个县进行： 华盛顿西部被以人口为基础的癌症所覆盖 监测系统（CSS），一个肿瘤登记处，参与了 国家监测流行病学和最终结果方案 癌症研究所.（阴茎、宫颈原位腺癌，以及 将包括另外10个县的阴道癌， 足够的样本量）。所有18-74岁的男性和女性， 恶性肿瘤将被确定并邀请参加，我们 预计成功面谈的个案数目如下： 宫颈浸润癌248例，肛门及肛周癌108例 外阴癌164例，阴茎癌48例， 宫颈腺癌96例，阴道癌60例 cases）.合格的受试者将是所有诊断为 在1994年7月至1998年6月的五年期间，这六种癌症。 将对病例和适当的对照组进行访谈，了解 性传播疾病，以及其他已知的风险因素， 每一个特定的网站。手术组织标本将从以下地点获得 所有的病例，并将探测人类乳头瘤病毒的证据， 分子杂交技术将采集血液样本， 所有病例和对照，并分析既往暴露于 单纯疱疹病毒2型和目前使用的几种类型的HPV 可用的测试将冷冻额外的血清以备将来测定 HPV抗体作为新的和/或更敏感的血清学检测， 为HPV而开发。

This is a proposal to continue our case-control studies investigating the role of human papillomaviruses (HPV) in the development of anogenital cancers. The study will be conducted primarily in three counties of Western Washington that are covered by the population-based Cancer Surveillance System (CSS), a tumor registry that participates in the Surveillance Epidemiology and End Results Program (SEER) of the National Cancer Institute. (Penile, adenocarcinoma in situ of the cervix, and vaginal cancers from ten additional counties will be included to provide a sufficient sample size.) All men and women aged 18-74 with one of six malignancies will be identified and invited to participate, and we estimate the following number of cases will be successfully interviewed: invasive cancer of the cervix (248 cases); anal and perianal cancer (108 cases); vulvar cancer (164 cases); penile cancer (48 cases); adenocarcinoma of the cervix (96 cases); and cancer of the vagina (60 cases). Eligible subjects will be all individuals with a diagnosis of one of these six cancers during a five-year period from July 1994 - June 1998. Cases and appropriate controls will be interviewed regarding a history of sexually-transmitted diseases, as well as other known risk factors for each specific site. Tissue specimens from surgery will be obtained from all cases and will be probed for evidence of human papillomavirus using molecular hybridization techniques. Blood samples will be collected for all cases and controls and analyzed for evidence of prior exposure to herpes simplex virus type 2 and for several types of HPV using currently available tests. Additional sera will be frozen for future determination of HPV antibodies as new and/or more sensitive serologic tests are developed for HPV.